Biocytogen has entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMice platform.
Under the terms of the agreement, Merck will have full access to Biocytogen’s RenMice platform to discover and develop fully human antibody therapeutics for an unlimited number of drug targets. Merck will be responsible for all clinical development, manufacturing, and commercialisation, and will provide Biocytogen with development and regulatory milestone payments. The official agreement was reached after an initial evaluation period.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “This agreement provides Merck with one of the most advanced fully human antibody discovery platforms. We are pleased that Merck recognised the potential of our RenMice platform to accelerate antibody development for novel and challenging targets.”
Based in Beijing, Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based therapeutics. The company has streamlined the drug development process through the use of RenMice for fully human antibody discovery, in vivo drug efficacy screening platforms and strong clinical development expertise. Biocytogen’s RenMice HiTS Platform aims to develop novel antibody drugs with first-in-class and/or best-in-class potential for more than 1,000 targets, and has resulted in collaborations with dozens of partners worldwide. The company's pipeline includes 12 core products; two products are in phase II MRCTs and two products are in phase I. For more information, visit www.biocytogen.com.
